Biofrontera Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-25. 3 holders' latest filing reports 5% or more of common shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Deutsche Balaton Aktiengesellschaft | 19.99% | 2,552,230 | SCHEDULE 13D/A, 2025-09-19 | 2025-09-16 |
| Rosalind Advisors, Inc. | 9.9% | 16,801,629 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| Orin Hirschman | 7.9% | 915,210 | SCHEDULE 13G/A, 2026-01-28 | 2025-12-31 |
Purpose of Transaction (Item 4)
Deutsche Balaton Aktiengesellschaft
Explanatory Note: There is no agreement among the Reporting Persons, written or oral, with respect to the acquisition, ownership, voting or disposition of any securities of the Issuer, and the Reporting Persons disclaim the existence of any group among them within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the "Act"), or the rules and regulations of the Securities and Exchange Commission ("SEC") promulgated thereunder. Except as otherwise set forth herein, all percentages herein are based on 10,668,442 shares of common stock outstanding as reported by the Issuer as of August 12, 2025, in its Quarterly Report on Form 10-Q filed on August 13, 2025, plus the 2,093,346 shares of the Issuer's common stock issuable upon conversion of BFAG's shares of Series D Preferred Stock. The information set forth in Item 3 of this Amendment No. 4 to Schedule 13D is hereby incorporated by reference into this Item 4. Prior to November 2, 2021, the Issuer was a wholly owned subsidiary of BFAG. On November 2, 2021, the Issuer consummated its initial public offering ("IPO") of 3,600,000 units, each consisting of (i) one share of common stock of the Issuer and (ii) one warrant entitling the holder to purchase one share of the Issuer's common stock at an exercise price of $5.00 per share, and such equity securities were registered under Section 12(b) of the Act. Immediately following the IPO, BFAG owned 8,000,000 shares of common stock, or approximately …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-09-19; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-25 | Deutsche Balaton Aktiengesellschaft | 4.86% | SCHEDULE 13D/A |
| 2025-08-11 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
| 2025-09-19 | Deutsche Balaton Aktiengesellschaft | 19.99% | SCHEDULE 13D/A |
| 2025-11-12 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
| 2026-01-28 | Orin Hirschman | 7.9% | SCHEDULE 13G/A |
| 2026-02-11 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
| 2026-08-12 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Biofrontera Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.